創傷生物製剤市場- 世界および地域別分析：製品別、地域別、国別分析、競合情勢：分析と予測（2023年～2030年）

世界の創傷生物製剤の市場規模は、2022年に18億5,140万米ドルとなりました。

同市場は、2030年末には33億2,150万米ドルに成長すると予測され、2023年から2030年にかけて7.71%のCAGRで拡大するとみられています。創傷生物製剤市場は、創傷や熱傷の治療需要の増加により、このような成長を遂げています。この成長の原動力には、熱傷の発生率の上昇、糖尿病性足潰瘍や褥瘡の有病率の拡大、創傷治療の強化を目的とした政府主導の取り組みなどがあります。

創傷生物製剤は、ヒト細胞、組織、天然物質などの生物学的資源に由来する先端医療材料です。これらの製品は、糖尿病性潰瘍、褥瘡、静脈性潰瘍などの慢性創傷や、怪我や手術による急性創傷など、様々なタイプの創傷を持つ患者の創傷治癒と組織再生を促進するために特別に設計されています。創傷生物製剤には、成長因子、細胞外マトリックス、細胞療法、生物工学的に作製された代用皮膚などがあり、これらはすべて、創傷閉鎖と組織修復をよりよく行うために、身体の自然治癒プロセスを促進することを目的としています。最近の市場開発としては、2023年3月にBioTissueがフロリダ州ドラルで施設の拡張と改修を完了したことが挙げられます。

当レポートでは、世界の創傷生物製剤市場について調査し、市場の概要とともに、製品別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 市場

• 製品定義
• 包含基準と除外基準
• 主な質問への回答
• 分析と予測ノート
• 主な調査結果

第2章 製品

• 製品セグメンテーション
• 製品概要
• 世界の創傷生物製剤市場（製品タイプ別）

第3章 地域

• 地域別概要
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• その他の地域

第4章 市場-競合ベンチマーキング

• 主な戦略と開発
• 主要企業エコシステム

第5章 調査手法

List of Figures

• Figure 1: Global Wound Biologics Market, $Million, 2022, 2026, and 2030
• Figure 2: Global Wound Biologics Market (by Region), $Million, 2022, 2026, and 2033
• Figure 3: Global Wound Biologics Market (by Product), $Million, 2022, 2026, and 2033
• Figure 4: Key Strategies Adopted by Market Players, 2021-2024
• Figure 5: Key Market Trends in Global Wound Biologics Market, 2023
• Figure 6: Strategic Initiatives, 2021-2024
• Figure 7: Share of Strategic Initiatives, 2021-2024
• Figure 8: Data Triangulation
• Figure 9: Top-Down and Bottom-Up Approach
• Figure 10: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Global Wound Biologics Market, Opportunities
• Table 3: Global Wound Biologics Market (by Product), $Million, 2021-2030
• Table 4: Global Wound Biologics Market (by Region), $Million, 2021-2030
• Table 5: North America Wound Biologics Market (by Product), $Million, 2021-2030
• Table 6: U.S. Wound Biologics Market (by Product), $Million, 2021-2030
• Table 7: Canada Wound Biologics Market (by Product), $Million, 2021-2030
• Table 8: Latin America Wound Biologics Market (by Product), $Million, 2021-2030
• Table 9: Argentina Wound Biologics Market (by Product), $Million, 2021-2030
• Table 10: Brazil Wound Biologics Market (by Product), $Million, 2021-2030
• Table 11: Chile Wound Biologics Market (by Product), $Million, 2021-2030
• Table 12: Colombia Wound Biologics Market (by Product), $Million, 2021-2030
• Table 13: Mexico Wound Biologics Market (by Product), $Million, 2021-2030
• Table 14: Europe Wound Biologics Market (by Product), $Million, 2021-2030
• Table 15: France Wound Biologics Market (by Product), $Million, 2021-2030
• Table 16: U.K. Wound Biologics Market (by Product), $Million, 2021-2030
• Table 17: Spain Wound Biologics Market (by Product), $Million, 2021-2030
• Table 18: Italy Wound Biologics Market (by Product), $Million, 2021-2030
• Table 19: Portugal Wound Biologics Market (by Product), $Million, 2021-2030
• Table 20: Netherlands Wound Biologics Market (by Product), $Million, 2021-2030
• Table 21: Ireland Wound Biologics Market (by Product), $Million, 2021-2030
• Table 22: Belgium Wound Biologics Market (by Product), $Million, 2021-2030
• Table 23: Switzerland Wound Biologics Market (by Product), $Million, 2021-2030
• Table 24: Norway Wound Biologics Market (by Product), $Million, 2021-2030
• Table 25: Denmark Wound Biologics Market (by Product), $Million, 2021-2030
• Table 26: Sweden Wound Biologics Market (by Product), $Million, 2021-2030
• Table 27: Finland Wound Biologics Market (by Product), $Million, 2021-2030
• Table 28: Germany Wound Biologics Market (by Product), $Million, 2021-2030
• Table 29: Czech Republic Wound Biologics Market (by Product), $Million, 2021-2030
• Table 30: Russia Federation Wound Biologics Market (by Product), $Million, 2021-2030
• Table 31: Poland Wound Biologics Market (by Product), $Million, 2021-2030
• Table 32: Austria Wound Biologics Market (by Product), $Million, 2021-2030
• Table 33: Romania Wound Biologics Market (by Product), $Million, 2021-2030
• Table 34: Slovakia Wound Biologics Market (by Product), $Million, 2021-2030
• Table 35: Greece Wound Biologics Market (by Product), $Million, 2021-2030
• Table 36: Turkey Wound Biologics Market (by Product), $Million, 2021-2030
• Table 37: Ukraine Wound Biologics Market (by Product), $Million, 2021-2030
• Table 38: Asia-Pacific Wound Biologics Market (by Product), $Million, 2021-2030
• Table 39: Australia Wound Biologics Market (by Product), $Million, 2021-2030
• Table 40: Japan Wound Biologics Market (by Product), $Million, 2021-2030
• Table 41: Malaysia Wound Biologics Market (by Product), $Million, 2021-2030
• Table 42: China Wound Biologics Market (by Product), $Million, 2021-2030
• Table 43: India Wound Biologics Market (by Product), $Million, 2021-2030
• Table 44: Thailand Wound Biologics Market (by Product), $Million, 2021-2030
• Table 45: South Korea Wound Biologics Market (by Product), $Million, 2021-2030
• Table 46: Rest-of-the-World Wound Biologics Market (by Product), $Million, 2021-2030
• Table 47: Key Companies, Global Wound Biologics Market

Global Wound Biologics Market Industry Overview

The global wound biologics market was valued at $1,851.4 million in 2022 and is anticipated to grow to $3,321.5 million by the end of 2030. This market is expected to expand at a compound annual growth rate (CAGR) of 7.71% between 2023 and 2030. Such growth is being experienced by the wound biologics market, owing to increasing demand for treating wounds and burn injuries. Drivers of this growth include the rising incidence of burn injuries, the expanding prevalence of diabetic foot ulcers and pressure ulcers, and government-led initiatives aimed at enhancing wound care treatments.

Market Introduction

Wound biologics products are advanced medical materials derived from biological sources such as human cells, tissues, or natural substances. These products are specifically designed to facilitate wound healing and tissue regeneration in patients with various types of wounds, including chronic wounds such as diabetic ulcers, pressure ulcers, and venous ulcers, as well as acute wounds from injuries or surgeries. Wound biologics can include growth factors, extracellular matrices, cellular therapies, and bioengineered skin substitutes, all aimed at promoting the natural healing processes of the body to achieve better wound closure and tissue repair. One recent development that has taken place in the market was in March 2023 when BioTissue completed a facility expansion and renovation in Doral, Florida, to support the growing demand and future expansion of its biologics product portfolio.

Market Segmentation:

Segmentation 1: by Product

• Growth Factors
• Skin Substitutes
• Topical Agents

Skin Substitutes to Lead the Global Wound Biologics Market (by Product)

Based on product, the wound biologics market is led by skin substitutes, which held a 63.78% share in 2022.

Segmentation 2: by Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Switzerland
  • Russian Federation
  • Turkey
  • Poland
  • Belgium
  • Sweden
  • Ireland
  • Norway
  • Austria
  • Denmark
  • Finland
  • Portugal
  • Czech Republic
  • Romania
  • Greece
  • Slovakia
  • Ukraine
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Malaysia
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Colombia
  • Argentina
  • Chile
• Rest-of-the-World

Regionally, North America maintains a dominant position, and it is expected to grow through a steady compound annual growth rate (CAGR) of 6.66% from 2023 to 2030. This sustained growth can be attributed to the region's advanced healthcare infrastructure, widespread awareness of wound management, and a notable increase in chronic wounds among its aging populace.

The emphasis on R&D in North America has also facilitated the emergence of innovative wound biologics products, supported by a strong regulatory environment and healthcare policies favouring advanced wound care solutions. The emphasis on R&D in North America has also facilitated the emergence of innovative wound biologics, supported by a strong regulatory environment and healthcare policies favouring advanced wound care solutions.

Asia-Pacific and the Rest-of-the-World regions are projected to experience the highest growth rates, with CAGRs of 11.49% and 11.29%, respectively, indicating a rapidly expanding market presence. The growth in these regions is likely driven by improving healthcare infrastructure, rising awareness of effective wound care, and increasing accessibility to advanced medical treatments. Overall, the wound biologics market globally has been characterized by regional growth patterns influenced by healthcare advancements, demographic shifts, and a collective focus on improving wound care outcomes.

Recent Developments in the Wound Biologics Market

• In May 2023, Cellularity disclosed a significant purchase order amounting to $45 million in accordance with the first private label agreement in the Middle East for Cellularity Inc.'s halal-certified biomaterial products. The products, namely Biovance, Biovance 3L, Interfyl, and CentaFlex have obtained halal certification.
• In January 2022, Gunze Limited announced the commencement of Epiflex sales by Gunze Medical Limited, marking the first and only approved product available in Japan. It is important to note that Epiflex is a registered trademark of MiMedx Group, Inc.

How can this Report add value to an Organization?

Product/Innovation Strategy: The report can highlight current market gaps and emerging patient needs, guiding companies in developing new products or enhancing existing offerings.

Growth/Marketing Strategy: Regional analysis offers insights into market size, growth rates, and competitive landscapes across different territories, assisting in strategic planning for geographic expansion or consolidation.

Competitive Strategy: Understanding future market trends and growth forecasts allows companies to anticipate changes in the competitive landscape, adjust their strategies accordingly, and identify early opportunities for innovation and expansion.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• The base year considered for the calculation of the market size is 2022. A historical year analysis has been done for the period FY2019-FY2021. The market size has been estimated for FY2022 and projected for the period FY2023-FY2030
• The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of upstream and downstream products of wound biologics.
• The market contribution of wound biologics products anticipated to be launched in the future has been calculated based on the historical analysis of the solutions.
• Revenues of the companies have been referenced from their annual reports for FY2022 and FY2023. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
• The market has been mapped based on the available wound biologics solutions. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in wound biologics, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and salespersons have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding the competitive landscape and business model
• Current and proposed production values of a product by market players
• Percentage split of individual markets for regional analysis

Secondary Research:

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• Segmentations and percentage shares
• Data for market value
• Key industry trends of the top players of the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The global competitive landscape of the wound biologics market is defined by the presence of several key players, each contributing to the market's growth through innovation, business expansion, funding, strategic partnerships, and a focus on expanding product portfolios. Leading companies in this space are distinguished by their commitment to research and development, which enables them to introduce advanced wound care solutions that address a range of needs, from basic wound protection to complex wound management scenarios.

Some prominent names established in this market are:

• AlloSource
• LifeNet Health
• Smith & Nephew plc.
• Sanara MedTech Inc.
• Mtf Biologics
• Becton, Dickinson and Company
• MiMedx Group, Inc.
• TissueTech, Inc.

Table of Contents

Executive Summary

1 Markets

• 1.1 Product Definition
• 1.2 Inclusion and Exclusion Criteria
  • 1.2.1 Inclusion
  • 1.2.2 Exclusion Criteria
• 1.3 Key Questions Answered
• 1.4 Analysis and Forecast Note
• 1.5 Key Findings

2 Products

• 2.1 Product Segmentation
• 2.2 Product Summary
• 2.3 Global Wound Biologics Market (by Product Type)
  • 2.3.1 Growth Factors
  • 2.3.2 Skin Substitutes
  • 2.3.3 Topical Agents

3 Regions

• 3.1 Regional Summary
• 3.2 North America
  • 3.2.1 U.S.
  • 3.2.2 Canada
• 3.3 Latin America
  • 3.3.1 Argentina
  • 3.3.2 Brazil
  • 3.3.3 Chile
  • 3.3.4 Colombia
  • 3.3.5 Mexico
• 3.4 Europe
  • 3.4.1 France
  • 3.4.2 U.K.
  • 3.4.3 Spain
  • 3.4.4 Italy
  • 3.4.5 Portugal
  • 3.4.6 Netherlands
  • 3.4.7 Ireland
  • 3.4.8 Belgium
  • 3.4.9 Switzerland
  • 3.4.10 Norway
  • 3.4.11 Denmark
  • 3.4.12 Sweden
  • 3.4.13 Finland
  • 3.4.14 Germany
  • 3.4.15 Czech Republic
  • 3.4.16 Russia Federation
  • 3.4.17 Poland
  • 3.4.18 Austria
  • 3.4.19 Romania
  • 3.4.20 Slovakia
  • 3.4.21 Greece
  • 3.4.22 Turkey
  • 3.4.23 Ukraine
• 3.5 Asia-Pacific
  • 3.5.1 Australia
  • 3.5.2 Japan
  • 3.5.3 Malaysia
  • 3.5.4 China
  • 3.5.5 India
  • 3.5.6 Thailand
  • 3.5.7 South Korea
• 3.6 Rest-of-the-World

4 Markets - Competitive Benchmarking

• 4.1 Key Strategies and Developments
• 4.2 Key Companies Ecosystem

5 Research Methodology

• 5.1 Data Sources
  • 5.1.1 Primary Data Sources
  • 5.1.2 Secondary Data Sources
  • 5.1.3 Data Triangulation
• 5.2 Market Estimation and Forecast